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ABSTRACT
N-Oxides of centrally acting analgesics generally have minimal
analgesic activity. However, the N-oxide of tramadol produced
dose-related, long-lasting antinociception in the mouse ab-
dominal irritant, 48#{176}Chot-plate, 55#{176}Chot-plate, and tail-flick
tests (ED50 = 15.5, 84.7, 316.4 and 138.2 mg/kg, p.o., respec-
tively). Tramadol N-oxide (T-N-O) (RWJ 38705) was also an-
tinociceptive in the 51 #{176}Chot-plate test in male (ED50 = 63.2
mg/kg, i.p.) and female (ED50 = 39.9 mg/kg, i.p.) rats. A char-
actenstic feature of T-N-O was an extended duration of action
in these tests (4-5 h). T-N-O had negligible affinity for opioid t
(K1 = 38.5 tM) & or K receptors (K > 1 00 M) and, in contrast
to tramadol, was essentially devoid of norepinephnne or sero-
tonin neuronal reuptake inhibitory activity (K > 100 pM). How-
ever, T-N-O displayed tramadol-like characteristics in vivo.
There were also significant amounts of tramadol in plasma after
T-N-O administration, and the levels resulting from equal oral
doses of T-N-O and tramadol were the same, suggesting that
the conversion of T-N-O to tramadol was rapid and essentially
quantitative. T-N-O was not readily metabolized to tramadol in
rat hepatic S9 fraction (< 2%), implying that the conversion
might occur in the gastrointestinal tract. Taken together, the
results suggest that T-N-O acts as a prodrug for tramadol.
T-N-O could offer the clinical benefits of an extended duration
of action and a “blunted” plasma concentration spike, possibly
leading to an enhanced side-effect profile.
Preparations ofN-oxides ofopium alkaloids were described
by Freund and Speyer (1910) and subsequently by Speyer
and Wieters (1921), Chang et at. (1950), and others (Kelentey
et al. , 1957; Fennessey, 1968). Despite retention of antitus-
sive activity (e.g.,Kelentey et at., 1957; Takagi and Fukuda,
1960), the N-oxides of these substances-e.g., morphine N-
oxide (genomorphine) and codeine N-oxide (genocodeine)-as
well as N-oxides of synthetic opioids, such as dihydromor-
phine N-oxide and dihydrocodeine N-oxide, have been re-
ported to possess only minimal or weak antinociceptive ac-
tivity (Kelentey et at., 1957; Takagi and Fukuda, 1960;
Fennessey, 1968). With only one exception (Polonowsky et
al., 1930), morphine N-oxide has been reported to have little
or no analgesic activity (Freund and Speyer, 1910; Rosentha-
ler, 1933; Keil et at., 1933; Anton et at., 1935). It has been
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suggested that this is because the tertiary nitrogen of mor-
phine cannot be made quaternary as in morphine N-oxide
without great diminution in analgesic activity. To the extent
that centrally mediated analgesia has become synonymous
with opioids, because of the clinical use of central analgesics
with limited mechanistic diversity, the generalization that
N-oxides of centrally acting analgesics are inactive has been
assumed tacitly.
Tramadol hydrochloride, (1RS,2RS)-2-[(dimethylamino)-
methylj-1-(3-methoxyphenyl)-cyclohexanol HC1, is a cen-
trally acting synthetic analgesic (Friderichs et al., 1978). It is
rapidly and almost completely absorbed after oral admiis-
tration, has a relatively low plasma-protein binding (approx-
imately 20%) and has a mean terminal plasma elimination
half-life of approximately 6-7 h. Tramadol is of particular
interest, because it has been reported to possess a favorable
profile compared with opiates of comparable efficacy (e.g.,
Arend et at., 1978; MUller-Limmroth and Krueger, 1978;
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(serotonin); HEPES, N-2-hydroxyethyl-piperazine-N’-2-ethanesulfonic acid; i.c.v., intracerebroventricular; i.p., intraperitoneal; i.t., intrathecal;
%MPE, percent maximal possible effect; M-N-O, morphine N-oxide; NE, norepmnephnne; NSAID, nonsteroidal antimnflammatory drug; PEI,
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Fig. 1. Chemical structure of tramadol, (1RS,2RS)-2-[(dimethylammno)
methyl]-1 -(3-methoxyphenyl)-cyclohexanol, and T-N-0 (RWJ 38705).
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Vogel et at., 1978; Cossmann and Wilsmann, 1987; Cossmann
and Wilsmann, 1988; Lehmann et at., 1990; Osipova et at.,
1991; Preston et at., 1991; Vickers et at., 1992) and its re-
ported minimal analgesic tolerance development (Floh#{233}et
at., 1978) and apparent low abuse liability (Yanagita, 1978;
Richter et at., 1980; Preston et at., 1991; Keup, 1993) suggest
that it might be suitable for a wide variety of painful condi-
tions and particularly appropriate in situations requiring
chronic use (Lee et at., 1993). However, the reported dual
mechanism of action of tramadol in animal models-weak
affinity for opioid receptors and enhanced synaptic norepi-
nephrine and serotonin levels (Hennies et at. , 1988; Reimann
et at., 1990; Raffa et at., 1992)-and a complementary and
synergistic interaction between its enantiomers (Raffa et at.,
1993)-apparently distinguishes tramadol from most other
centrally acting analgesics. For this reason, it was of interest
to test the N-oxide oftramadol (fig. 1). Its unexpected antino-
ciceptive activity, and the long duration of its effect, is of
interest from both a basic research and therapeutic perspec-
tive.
Methods
Compounds. Tramadol hydrochloride, (1RS,2RS)-2-[(dimethyl-
amino)methyll-1-(3-methoxyphenyl)-cyclohexanol hydrochloride was
supplied by Grunenthal GmbH (Aachen, Germany). T-N-O (RWJ
38705) was prepared as follows. Tramadol hydrochloride was con-
verted to its free base in water (pH > 9) and then extracted with
ether. The solid was then heated under a high vacuum to remove as
much water as possible. The material was dissolved in methanol and
30% H202 was added. The solution was stirred for 3 h, then addi-
tional H202 was added. The reaction was stirred for 2.5 days at room
temperature. #{176}2 Ofl carbon was then added to the reaction mix-
ture, and very gentle foaming took place. Additional Pt02 was added,
and the reaction mixture was stirred overnight and then filtered
through filter aid. The filtrate was concentrated under vacuum while
being heated to a temperature less than 40#{176}C.The residue was taken
up in methylene chloride. The solution was diluted with ethyl acetate
and filtered though a nylon filter membrane (0.45  pore size) to
yield a clear colorless filtrate. The filtrate was then concentrated,
and ethyl acetate was added continuously to maintain a constant
volume while the solution was heated until a vapor temperature of
74#{176}Cwas reached. The solution was cooled to room temperature. The
solid was collected by filtration, washed with ethyl acetate and dried
in vacuo to yield T-N-O. T-N-O is a colorless, slightly hygroscopic
crystalline compound (melting point 159-160#{176}C) that is very soluble
in water. All ofthe other compounds were obtained from commercial
sources (e.g., Sigma Chemical Co., St. Louis, MO and Research
Biochemicals Inc., Natick, MA).
I Tramadol I
In Vitro Tests
Opioid receptor binding assays. Male Wistar rats, 150 to 250 g
(Charles River Laboratories, Kingston Facility, Stoneridge, NY),
were euthanized by cervical dislocation, and their brains were re-
moved and placed immediately into an ice-cold aqueous solution of
50 mM Tris Cl (pH 7.4 at 23#{176}C).The forebrains were separated from
the remainder ofthe brain by coronal transection, beginning dorsally
at the colliculi and passing ventrally through the midbrain-pontine
junction. After dissection, the forebrains were homogenized in 10
volumes of an aqueous 50 mM Ths-buffered solution in a Teflon#{174}
glass homogenizer (Thomas Scientific, Swedesboro, NJ). The fore-
brain homogenate was diluted to a concentration of 1.0 g of forebrain
tissue per 100 ml of the Tris-buffered solution and centrifuged at
39,000 x g for 10 mm. The sedimented material was resuspended in
the same volume of Ths-buffered solution using several brief pulses
of a Janke and Kunkel Ultra-Turrax tissue homogenizer. This par-
ticulate preparation was used for the t- and &-opioid binding assays.
For the K binding assay, this preparation was preincubated at room
temperature for 30 mm, then centrifuged and resuspended as de-
scribed above. Assay volumes were 1.0 ml (.t and 5) or 2.0 ml (K), and
the tritiated ligands were [3H]-DAMGO (0.33 nM) (g.t), [3H]-DPDPE
(2.2 nM) (8) and [3H]-U69,593 (0.49 nM) (K). After incubation at 25#{176}C
for 1.0 h (L and 6) or 1.5 h (K), the tube contents were filtered through
presoaked (0.5% PEI for  and 5, 0.1% BSA for K) Whatman GFIB
filter sheets on a Brandel cell harvester. The tubes and filters were
rinsed three times with 4.0 ml of 10 mM HEPES (pH 7.4), and the
radioactive content of the filter circles was determined using For-
mula 989 (New England Nuclear, Boston, MA) in a scintillation
counter.
Uptake assays. Rats were sacrificed, and brain tissue was dis-
sected (medulla for NE and cortex for 5-HT) and homogenized in 30
volumes (mug tissue) of HEPES-buffered sucrose (10 mM HEPES,
300 mM sucrose, pH 7.4 at 23#{176}C).The resulting homogenate was
centrifuged at 1,000 x g for 10 mm, and the resulting supernatant
was centrifuged at 42,000 X g for 15 mm. The P2 fraction was
resuspended in 10 volumes of HEPES-sucrose. The incubation me-
dium contained 1.5 mM KHPO4, 140 mM NaC1, 1.3 mM CaCI2, 2.0
mM MgCl2, 5 mM (+)-glucose, and 10 mM HEPES (pH 7.5 at 23#{176}C).
Each sample contained 0.7 ml of incubation medium, 0.1 ml of test
compound, and 0.1 ml of [3H]-ligand (10 nM of [3H1-NE for NE
reuptake or 10 nM [3H1-5-HT for 5-HT reuptake) (both dissolved in
incubation medium), and 0.1 ml ofthe resuspended P2 fraction ( 0.3
mg protein). Samples were incubated in groups of 12 that contained
1 control, 1 blank, and 10 test samples. The samples were incubated
at 37#{176}Cfor 5 mm (NE) or 6 mm (5-HT), and the uptake reaction was
stopped by the rapid addition of 2.0 ml of ice-cold incubation me-
dium. The synaptosomes were collected on LKB (Wallac, Turku,
Finland) filter mats and were rinsed with 2.0 ml of cold incubation
medium. The radioactivity was quantified in an LKB12O5 BetaPlate
scintillation counter (using LKB BetaPlate scintillation fluid).
Analysis of receptor binding and uptake assay data. K,
values were determined from concentration-response curves consist-
ing of 5 to 10 concentrations done in duplicate or triplicate. The data
were analyzed using LIGAND (Munson and Rodbard, 1980), a pro-
gram that uses nonlinear curve fitting techniques to obtain optimal-
fit models of the data. The nonspecific binding was computed by
LIGAND as a fitted parameter. Each concentration-response curve
was replicated two or three times in independent experiments. The
replicate determinations usually only differed from each other by
less than 10%. The K, values reported are the mean of the replicate
determinations.
Plasma level determinations. Mice were administered tram-
adol hydrochloride or T-N-O (12 or 40 mg/kg) prepared as a solution
in distilled water. At 0.5, 1, 2, 3, 4, 6, and 8 h later, the mice were
J anesthetized (two per time point) with C02, and blood was obtained
via cardiac puncture. Control plasma was obtained from nontreated
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samples were assayed for tramadol by gas chromatography. Noncom-
partmental pharmacokinetic analysis was performed.
Rat hepatic metabolism assay. The in vitro metabolism of
T-N-O was investigated using an hepatic 9,000 x g supernatant (59)
fraction from male, 250 to 300 g, Crl:CDeBR VAFIP1us rats
(Charles River Laboratories, Stone Ridge, NY). The rats were eutha-
nized (decapitated), and the liver was removed, minced, and homog-
enized (using a Brmkmann Polytron#{174}) in cold Tris buffer to a total
volume of approximately 4 X the liver wet weight. The homogenate
was centrifuged at 9,000 x g for 30 mm, then the 59 was removed for
use in the analysis. T-N-O was incubated (100 .tg/ml) with 59 in the
presence of an NADP-generating system (Tris buffer, pH 7.4, 37#{176}C).
Aliquots were removed at 30 and 60 mm after initiation. Unchanged
T-N-O and metabolites were isolated and identified using solvent
extraction, Sciex API III (lonapray) mass spectroscopy and MS/MS
techniques, and by comparison with synthetic samples of tramadol
and its metabolites.
In Vivo Tests
&nime1. The mice used for the abdominal irritant, 48#{176}Chot-
plate, 55#{176}Chot-plate, and tail-flick tests were male, 18 to 24 g,
pathogen-free albino Crl:CD-1#{174}(ICR)BR (Charles River Laborato-
ries; Kingston Facility, Stone Ridge, NY) and the rats (51#{176}Chot-plate
test) were either male, 80 to 140 g, or female, 112 to 138 g, Sprague-
Dawley (Charles River Laboratories; Kingston Facility, Stone Ridge,
NY). All of the animals were maintained in a virus-free, climate-
controlled room on a 12 h light/dark cycle (lights on at 0600 h) with
food and water available ad libitum up to the time of the test. All
compounds were dissolved in distilled water (vehicle) and were ad-
ministered in a volume of 10 mI/kg (mice) or 2 mI/kg (rats) unless
otherwise noted. All ofthe testing was performed in accordance with
the recommendations and policies of the National Institutes of
Health and Johnson & Johnson guidelines for the handling and use
of laboratory animals.
Mouse acetyicholine-induced abdominel constriction test.
The procedure with minor modifications was that described by Col-
her et a!. (1968). Test drugs or appropriate vehicle were adminia-
tered by the desired route and, at specified time intervals later, the
animals received an i.p. injection of 5.5 mg/kg of acetylcholine bro-
mide. The mice were then placed into large glass bell jars and
observed. The percent of inhibition of acetylcholine-induced behav-
ioral response (antinociception) was calculated as follows:
% Antinociception = 100 x (Number ofNonresponders)/(Number ofA
Mice in Group).
The estimated ED value (the dose of agonist calculated to pro-
duce 50% antinociception) and the corresponding 95% fiducial inter-
vals were determined using the probit analysis of Litchfield and
Wilcoxon (1949), including a  test for linearity.
In some of the experiments, naloxone hydrochloride was adminis-
tered s.c. concurrently with T-N-O.
Mouse/rat hot-plate and tail-flick tests. The hot-plate test,
with minor modifications, was that described by Eddy and Leimbach
(1953) and O’Callaghan and Holtzman (1975). The hot-plate (Omni-
tech Electronics, Inc., Columbus, OH) was maintained at 48.0 (±
0.5)#{176}Cor 55.0 (± 0.5)#{176}Cfor mice or 51.0 (± 0.5)#{176}Cfor rats. An animal
was placed on the heated surface and the time interval (seconds)
between placement and a shaking, licking or tucking ofthe hind paw
was recorded as the predrug latency response. This same procedure
was repeated at specified times after drug administration.
The tail-flick test, described by D’Ainour and Smith (1941), was
used with minor modifications. Animals responded to a focused heat
stimulus by “flicking” or removing their tail from the path of the
stimulus, thereby exposing a photocell located in the apparatus
immediately below the tail. The reaction time was automatically
recorded. At designated times after drug administration, the proce-
dure was repeated and reaction times compared with predrug reac-
tion times.
For the hot-plate and tail-ifick tests, the percent maximum possi-
ble antinociceptive effect (% MPE) was determined using the for-
mula:
% MPE = 100 x (Test latency - Predrug latency)/(Cutoff time -
Predrug Latency)
using the predrug latency ofeach animal and cutoiftime established
to prevent injury to the animal. The cutoff time was 20 a for the
tail-flick test (based on control reaction times offl-9 see), 60 a for the
55#{176}Chot-plate test (based on control times of 10-20 a), and 90 a for
the 48#{176}Cand 51#{176}Chot-plate teats (based on control times of25-40 a).
The ED50 value and 95% confidence intervals were determined using
a computer-assisted linear regression analysis of the dose-response
curve, including an analysis of variance test for linearity. In some of
the experiments, naloxone hydrochloride was administered s.c. con-
currently with T-N-O.
Results
Antinociception tests. T-N-O produced dose-related an-
tinociception in all of the tests in mice and rats (fig. 2). The
ED50 values (and 95% fiducial intervals) in mice after par-
enteral administration ranged from 15.5 (10.3-20.8) mg/kg
p.o. in the acetylcholine-induced abdominal irritant test to
316.4 (253.5-405.3) mg/kg p.o. in the 55#{176}Chot-plate test
(table 1). T-N-O also produced dose-related antinociception in
the 51#{176}Chot-plate test, ED50 = 63.2 (50.5-77.9) mg/kg, i.p. in
male and 39.9 (26.1-66.1) mg/kg i.p. in female rats. The
antinociceptive effect was apparent within 15 ruin and lasted
for approximately 4 to 5 h. Compared with tramadol, the
antinociceptive effect of an equi-analgesic dose ofT-N-O was
of slightly slower onset, but of significantly longer duration
(fig. 3).
Naloxone interaction studies. The T-N-O p.o. EDoc
value in the mouse abdominal irritant test was determined at
the time ofpeak effect (30 mm), and this dose (40 mg/kg) was
retested to ensure an approximately 90% response. Naloxone
administered concurrently with this dose of T-N-O attenu-
ated T-N-O-induced antinociception, but naloxone failed (up












Fig. 2. Antinociceptive dose-response curves for T-N-O in the mouse
abdominal initant test (MAlT), 48#{176}Cand 55#{176}Chot-plate tests (48 HP
and 55 HP, respectively), tail-flick test (IF) and rat 51 #{176}Chot-plate test
[male (51 HP M) and female (51 HP F)]. For the MAlT, antinociception is
expressed as the percent of the group (n = 15 per dose). For the other
tests, antinociception is expressed as the %MPE ± S.E.M. (n = 10 per
dose). The data for the MAlT were obtained 30 mm after dosing; for the
other tests, at the time of peak antinociceptive effect (see table 1).
ComparIson of T-N-O-lnduced and tramadol-Induced antinociception in mice and rats
All values are expressed as the ED (95% confIdence intervals) in mg/kg at time of peak effect.
Test Route T-N-0 Tramadol5 Ratiob
Mice
Abdominal irritant p.o. 15.5 (10.3-20.8) at 30 mm 5.4 (4.1-7.1) at 30 mm 2.87
Hot-plate (48#{176}C) p.o. 84.7 (71 .3-98.5) at 120 mm 28.3 (23.0-33.9) at 30 mm 2.99
Hot-plate (55#{176}C) p.o. 316.4 (253.5-405.3) at 60 mm 97.6 (75.5-120.1) at 15 mm 3.24
Tail-flick p.o. 138.2 (99.6-208.5) at 60 mm 78.8 (67.0-93.3) at 1 5 mm i 
Rats
Hot-plate (51#{176}C)
-male i.p. 63.2 (50.5-77.9) at 120 mm 19.5 (10.3-27.5) at 15 3.24
-female p. 39.9 (26.1-66.1) at 120 mm 8.2 (6.6-10.6) at 30 mm 4.87
a From Raffa et a!., 1992.
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Fig. 5. Mean plasma concentration (conc.) of tramadol in mice after
administration of a single dose of tramadol (40 mg/kg, p.o.) (squares)
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Fig. 3. Time-course of the antinociceptive effect of tramadol (1 2 mg/
kg, p.o.) and T-N-O (40 mg/kg, p.o.) in the mouse abdominal irritant
test. n = 15 mice per dose per time.
similar finding was observed previously for an EDoo dose of
tramadol in this test (20.0 mg/kg, i.p.) (Raffa et at., 1992), in
contrast to the complete reversal by naloxone (0.002-0.5
mg/kg, s.c.) of ED doses of morphine (2.0 mg/kg, i.p.) or
codeine (16.0 mg/kg, i.p.) (fig. 4).
Receptor binding and uptake assays. T-N-O displayed
only weak affinity (K = 38,500 nM) for .t opioid receptors
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Fig. 4. Naloxone inhibition of morphine (0), codeine (0), tramadol ()
or T-N-O (A) antinociception in the mouse abdominal irritant test.
Naloxone (s.c.) and the approximate ED dose (i.p.) of morphine (2
mg/kg), codeine (1 6 mg/kg), tramadol (20 mg/kg), or T-N-O (40 mg/kg)
were administered concurrently; antinociception was assessed at the
time of peak effect (15 or 20 mm later). Dotted-line data redrawn from
Raffa et a!. (1992). n = 10 to 20 mice per dose.
affinity (Ij > 100 .tM) for  or K opioid receptors. T-N-O did
not inhibit the synaptosomal reuptake of norepinephrine or
serotonin (K values > 100 SM).
Tramadol plasma levels. After the oral administration of
T-N-O to mice, significant plasma levels of tramadol were
observed. Moreover, the plasma tramadol concentration
time-course was consistent with the T-N-O antinociceptive
time-course. In contrast to the rapid attainment of Cmax (
0.5 h) and rapid decline in tramadol plasma levels (t[112]
1 h) after tramadol administration, tramadol levels increased
more gradually (Cm,, 2 h) and were maintained for a
longer period after T-N-O administration (fig. 5). For the two
doses, the tramadol AUCs were essentially the same after
either tramadol or T-N-O administration, (table 2), suggest-
ing complete conversion. Also consistent with the conversion
of T-N-O to tramadol, the elimination half-life of tramadol
was approximately the same (#{176}#{176} h) after either tramadol or
T-N-O administration.
Rat hepatic metabolism assay. Unchanged T-N-O ac-
counted for the majority (- 70%) ofthe drug-related analytes
in the S9 samples. Eight metabolites were tentatively iden-
tifled on the basis of MS data. The prevalence (percent of the
analytes) of each was less than 10%, including tramadol (<
2%).
Parenteral routes of administration. T.-N-O also pro-
duced dose-related antinociception via i.p. or s.c. administra-
tion. However, the duration of the antinociceptive effect was
less than that after p.o. administration. Also, unlike the case
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Fig. 7. Time-course of antinociceptive effect (%MPE ± S.E.M.) of 640
mg/kg, p.o. T-N-0 in the mouse tail-flick test (n = 1 0). The asterisk
denotes the lethal effect of this same dose of tramadol within 5 mm.
Fig. 6. Time-course of the antinociceptive effect in the mouse abdom-
inal irritant test of: (A) tramadol (12 mg/kg, i.p.); (B) T-N-0 (40 mg/kg,
i.p.); (C) tramadol (12 mg/kg, s.c.); and (D) T-N-0 (40 mg/kg, s.c.). n =
15 per dose per time.
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TABLE 2
Comparison of tramadol pharmacokinetic parameters after the oral administration of tramadol or T-N-O to mice
All values are for the composite curves resulting from plasma measurement in 2 to 3 mice per time-point for each dose.
Treatment Dose (mg/kg) Cma. (ng/ml) Tmax (h) AUC (ng . h/mi) t1/2 (h)
Tramadol 12 40.5 0.5 43.6 0.91
T-N-0 12 20.5 0.5 44.7 0.97
Tramadol 40 172.5 0.5 219.0 1.03
T-N-0 40 103.5 2.0 281.9 0.81
ciceptive doses of tramadol and T-N-O after either i.p. or s.c.
administration were not as disparate (fig. 6). In the case of
S.C. administration, there was essentially no difference in the
duration of antinociceptive effect of tramadol and T-N-O. In
the case ofi.p. administration, the duration ofeffect of T-N-O
was greater than that of tramadol, the difference being in-
termediate between that of p.o. and s.c. administration.
High dose administration. T-N-O could be administered
up to very large doses. For example, a dose of 640 mg/kg, p.o.
produced long-lasting (about 7 h) antinociception in the
mouse tail-flick test (fig. 7). In contrast, the same dose of
tramadol was lethal to nine of ten mice within 5 mm.
Discussion
The N-oxides of morphine (genomorphine), codeine (geno-
codeine), dihydrocodeine, and dihydromorphine have mini-
mal or only weak antinociceptive effect (reported in Kelentey
et al., 1957; Fennessey, 1968). Thus, it was surprising that
the N-oxide of tramadol produced dose-related antinocicep-
tion in all ofthe tests examined, including the mouse abdom-
ma! irritant, hot-plate (48 and 55#{176}C)and tail-flick tests and
the rat hot-plate (51#{176}C)test. In each of the tests, the antino-
ciception was dose-related, of rapid onset, and of extended
duration. The potency ratio of T-N-O compared with tram-
adol was similar in each of the tests, ranging from about 1.8
to approximately 4.9. The ratio was also similar for male and
female rats (3.2 and 4.9, respectively). However, T-N-O was
notably devoid of significant in vitro activity. It did not bind
(up to 100 jtM) to opioid  or K receptors and had a K, value
at j. opioid receptors of only 38.5 MM. Likewise, it did not
have detectable activity (up to 100 M) at NE or 5-HT neu-
ronal reuptake sites. However, T-N-O displayed tramadol-
like characteristics in vivo. Specifically, T-N-O shared with
tramadol the unusual partial blockade by naloxone in some
tests. This profile suggested that T-N-O might produce its
effect by being converted to tramadol.
Examination of the pharmacokinetic profile of T-N-O re-
vealed that 1) the plasma from mice administered T-N-O
contained significant levels of tramadol, 2) essentially all
administered T-N-O was converted to tramadol over the du-
ration ofthe T-N-O-induced antinociception, and 3) the elim-
ination half-life of tramadol was the same whether it was
administered directly or arose as a consequence of T-N-O
administration. Definitive determination of the site of this
conversion was beyond the scope of the present study. How-
ever, some of the results seem to suggest that conversion
might occur somewhere in the gastrointestinal tract. Bio-
transformation in the liver does not seem to be a predomi-
nant factor, because there was negligible metabolism of T-
N-O in rat hepatic S9 (unless in vivo metabolism differs
significantly). For a wide range of structurally dissimilar
N-oxides, NADPH and cytochrome P-450s, and other
hemeproteins, mediate two-electron reduction under hypoxia
(Patterson, 1993). Reductive metabolism of N-oxides can oc-
cur in anaerobic intestinal gut microflora, intestinal cells,
hepatic cells or other cells. As an example, reductive metab-
olism ofloperamide N-oxide to loperamide (an antidiarrheal)
has been shown to be carried out by intestinal gut microflora
(Lavrijsen et at. , 1995) and intestinal epithelium (Van Bei-
jsterveldt et at., 1995). When morphine N-oxide (M-N-O) is
administered to rats, approximately 61% M-N-O equivalent
appears in the urine as morphine (Heimans et at., 1971).
Reduction is the only metabolic pathway demonstrated for
M-N-O (e.g. , there is no evidence of demethylation of either
M-N-O or of codeine N-oxide), possibly because N-oxides are
generally less lipid soluble than their parent bases (Culve-
nor, 1953) and penetration into microsomes is inhibited. Al-
ter morphine administration, a small amount of M-N-O is
detected in the urine of guinea pigs (2% of the amount of free
morphine), but not in other species (rats, rabbits, cats, mon-
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keys or humans) (Yeh et at., 1979). T-N-O has not been
described as a metabolite of tramadol. The finding in the
present study that the difference in the durations of antino-
ciceptive effect ofT-N-O and tramadol occurs in the order p.o.
> i.p. > s.c. suggests that there is some delay ofT-N-O effect
imposed within the gastrointestinal/portal system. Perhaps
the greater lipophobicity of T-N-O compared with tramadol
results in some depot of T-N-O and, essentially, the “slow
release” of tramadol into the general circulation in addition
to the “first pass” metabolism of T-N-O in the gastrointesti-
nal tract. Such a process would be consistent with the rela-
tively level tramadol plasma concentration profile after T-
N-O administration, compared with the profile after a single
bolus administration of tramadol itself-which includes an
early concentration spike.
It appears that the acute toxicity of T-N-O is lower than
that of tramadol. This is similar to the findings that the
N-oxides of morphine and codeine each have lower toxicities
than the parent compounds (Takagi and Fukuda, 1960; Fen-
nessey and Fearn, 1969), and that M-N-O does not have
behavioral, cardiovascular, or respiratory effects different in
degree from the parent compound (Fennessey, 1969). Specu-
latively, the lower toxicity of T-N-O might derive from the
blunted tramadol plasma concentration after T-N-O admin-
istration as opposed to tramadol administration (i.e. , absence
of the concentration spike). A similar explanation might be
used for the reported absence of vomiting in dogs after the
administration of M-N-O, as opposed to morphine (Fennes-
sey, 1969). Of potentially more long-term toxicological con-
cern regarding N-oxide compounds is the possible formation
of hydroxyl amines via metabolic N-demethylation. Some
hydroxyl amines are mutagenic; others are not. Examples of
tertiary amine drugs shown to be metabolized to nontoxic
N-oxides include chlorpromazine (Beckett, 1968), imipra-
mine (Bickel, 1969), chlorcyclizine (Burns and Phillips,
1966), dimethylamine (Ziegler and Pettit, 1964), nicoti-
namide (Chaykin and Bloch, 1959), and trimethylamine
(Baker and Chaykin, 1962). In an effort to address this issue,
we synthesized RWJ 46490, tramadol N-hydroxyl. Tramadol
N-hydroxyl, like T-N-O, was found to be not mutagenic in the
bacterial/microsomal activation assays using Satmonetta ty-
phimurium (Ames et at., 1975) (Dr. James W. Oldham, The
R.W. Johnson Pharmaceutical Research Institute, Spring
House, PA, data not shown). Examples of clinically used
N-oxide prodrugs are chiordiazepoxide, minoxidil, and a
number of antitumor agents (e.g., acridine carboxamide and
chiorambucil N-oxide) that are believed to be reduced enzy-
matically within hypoxic tumor cells to their active metabo-
lites (Robertson et at. , 1993; Chandler and Kirkpatrick,
1994).
In summary, T-N-O (RWJ 38705) produced dose-related
antinociception in mice and rats and in multiple tests (ab-
dominal irritation, hot-plate and tail-flick). Because of its
lack of inherent activity in vitro at opioid or monoamine
reuptake sites, T-N-O seems to produce its antinociceptive
effect by an indirect mechanism-most likely through con-
version to tramadol. Consistent with this interpretation are
the findings of plasma levels of tramadol after T-N-O admin-
istration and the characteristic “tramadol-like” properties of
T-N-O in vivo (i.e., only partial naloxone-reversibility in most
tests). Compared with tramadol, T-N-O could offer the fol-
lowing clinical benefits: 1) a longer duration of action and 2)
a “blunted” plasma concentration spike, possibly leading to
lower toxicity or less nausea/vomiting side effects. More
broadly, the results ofthe present study demonstrate that an
N-oxide ofone centrally acting analgesic (tramadol) can have
significant antinociceptive activity.
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